Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH

Inventiva Appoints Chris Benecchi as Chief Operating Officer

MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies

MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development

Sofinnova Partners appoints David Evans as Partner

Inventiva Strengthens Board of Directors with Appointment of Three Distinguished Life Sciences Leaders

Tom Burt, partner at Sofinnova Partners, joined Edison Group’s Open House Global Healthcare Event. His panel discussed some of the scenarios that are likely to play out in 2022 for biotech in public and private equity markets and M&A. 

Tom Burt, partner at Sofinnova Partners, joined Edison Group’s Open House Global Healthcare Event. His panel discussed some of the scenarios that are likely to play out in 2022 for biotech in public and private equity markets and M&A. View the replay here. 

